ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2015
Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syndrome coronavirus infections.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Interleukin-6 in Covid-19: A systematic review and meta-analysis.Reviews in medical virology · 2020Pooled it
- The role of extracellular histones in COVID-19.Journal of internal medicine · 2023Review
- Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2022Review
- A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease.Saudi journal of biological sciences · 2022Review
- Clinical features and mechanistic insights into drug repurposing for combating COVID-19.The international journal of biochemistry & cell biology · 2022Review
- Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update.Infectious diseases (London, England) · 2021Article
- Genetic Risk Factors for the Development of COVID-19 Coronavirus Infection.Russian journal of genetics · 2021Article
- Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Review
- The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019.Journal of translational medicine · 2020Review
- Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.Virus research · 2020Review
- Middle East Respiratory Syndrome Coronavirus and Severe Acute Respiratory Syndrome Coronavirus.Seminars in respiratory and critical care medicine · 2020Review
- Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Article
- Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Review
- Reducing mortality from 2019-nCoV: host-directed therapies should be an option.Lancet (London, England) · 2020Article
- The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19).Therapeutics and clinical risk management · 2020Review
- Article
- Review
- The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.PLoS neglected tropical diseases · 2017Review
- Middle East Respiratory Syndrome.The New England journal of medicine · 2017Article
- The Middle East Respiratory Syndrome Coronavirus - A Continuing Risk to Global Health Security.Advances in experimental medicine and biology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three years after its first discovery in Jeddah Saudi Arabia, the novel zoonotic pathogen of humans, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) continues to be a major threat to global health security.(1) Sporadic community acquired cases of MERS continue to be reported from the Middle East. The recent nosocomial outbreaks in hospitals in Seoul, Korea and at the National Guard Hospital in Riyadh, Saudi Arabia indicate the epidemic potential of MERS-CoV. Currently there are no effective anti-MERS-CoV anti-viral agents or therapeutics and MERS is associated with a high mortality rate (40%) in hospitalised patients. A large proportion of MERS patients who die have a range of pulmonary pathology ranging from pneumonia to adult respiratory distress syndrome with multi-organ failure, compounded by co-morbidities, reflecting a precarious balance of interactions between the host-immune system and MERS-CoV. Whilst we wait for new MERS-CoV specific drugs, therapeutics and vaccines to be developed, there is a need to advance a range of Host-Directed Therapies. A range of HDTs are available, including commonly used drugs with good safety profiles, which could augment host innate and adaptive immune mechanisms to MERS-CoV, modulate excessive inflammation and reduce lung tissue destruction. We discuss the rationale and potential of using Host-Directed Therapies for improving the poor treatment outcomes associated with MERS. Carefully designed randomized controlled trials will be needed to determine whether HDTs could benefit patients with MERS. The recurrent outbreaks of MERS-CoV infections at hospitals in the Middle East present unique opportunities to conduct randomized clinical trials. The time has come for a more coordinated global response to MERS and a multidisciplinary global MERS-CoV response group is required to take forward priority research agendas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.